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2 ABSTRACT 
Dendritic cells (DCs) have been shown being pivotal in the immune system by recognizing 
antigens and presenting them to leukocytes inducing a proper and specific immune response. 
The DCs are the most powerful Antigen Presenting Cells (APCs) and recently have been 
identified as one of the most important tools for immune therapies against different types of 
cancer. Until now the molecular mechanisms underlying the maturation of monocyte-derived 
dendritic cells are still mostly unknown. The aim of this thesis is to start an analysis about the 
role of PI3K and ROCKII pathways during the maturation of monocyte-derived dendritic 
cells and to investigate whether and how these pathways are affected by tumors. 
The preliminary results obtained during this thesis showed that both PI3K and ROCKII 
strongly affect the maturation process of human DCs, at least under in vitro culture condi-
tions. 
PI3K positively acts upon both morphological and functional maturation. Indeed, the chemi-
cal specific inhibition of PI3K correlates with a strong down regulation of the expression pat-
tern of surface markers, typical of mature DCs as well as with the absence of down regulation 
of characteristics typical of immature DCs, such as high migration and phagocytosis. These 
changes are additionally accompanied by altered endogenous protein levels of B-Raf, JNK1, 
MEK and ERM, which strengthens the assumption of PI3K being a regulator of parallel mo-
lecular pathways such as the MAPK-pathway. PI3K does not appear to alter the secretion of 
IL-10 and IL-12. For the preliminary results obtained in this thesis, PI3K appears to be par-
ticularly relevant only at specific time-windows during the DC maturation, rather than 
through the entire differentiation. Anyhow, such findings require further investigation in a 
statistical-relevant study.  
The effects observed upon ROCKII chemical inhibition were predominantly shown on cy-
toskeleton-related functions such as migration and phagocytosis, which were accompanied by 
changes in the endogenous ERM protein levels. Moreover, ROCKII inhibition affected the 
levels of B-Raf and JNK1 protein as well. Strikingly, ROCKII markedly altered the secretion 
of IL-10 and IL-12 without lowering the potential to induce a T cell response suggesting the 
existence of an alternative interleukin-independent mechanism for the activation of T cells by 
DCs, possibly through direct contact between the two types of cells. ROCKII inhibition 
mostly affected DCs by increasing the number of dendrites and by powerfully enhancing cell 
adherence. The effects of ROCKII inhibition on the expression of maturity-associated mark-
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ers on the DC surface were minor, although such issues require further investigation in a sta-
tistical-relevant study. 
Although some differences in the response to PI3K or ROCKII chemical inhibition were ob-
served between DCs derived from healthy controls and patients, further studies are required to 
exclude individual-related bias. 
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3 ZUSAMMENFASSUNG 
Es wurde gezeigt, dass dendritische Zellen eine entscheidende Rolle im Immunsystem 
spielen, da sie Antigene erkennen und an Leukozyten präsentieren können um eine passende 
Immunantwort auszulösen. Daher stellen DCs die stärksten Antigen-präsentierenden Zellen 
dar und wurden vor kurzem als eines der wichtigsten Werkzeuge zur Immuntherapie gegen 
unterschiedliche Krebsarten identifiziert. Die der Reifung von Monozyten-abstammenden 
dendritischen Zellen zugrunde liegenden molekularen Mechanismen sind bis heute 
größtenteils unbekannt. Ziel dieser Diplomarbeit war es eine Analyse der Rolle der PI3K und 
ROCKII Signalwege während der Reifung von dendritischen Zellen zu beginnen und zu 
untersuchen, ob und wie diese Signalwege durch Tumore beeinflusst werden. 
Die vorläufigen Ergebnisse dieser Diplomarbeit zeigten, dass PI3K und ROCKII den 
Reifungsprozess von humanen DCs, zumindest unter in vitro Bedingungen, stark 
beeinflussen. 
PI3K beeinflusst die morphologische und funktionelle Reifung positiv. Tatsächlich korreliert 
die chemische Inhibierung von PI3K mit einer starken Verminderung der Expresssionsmuster 
von Oberflächenmarkern, die typisch für reife DCs sind und auch mit einer fehlenden 
Verminderung von Charakteristiken typisch für unreife DCs, wie zum Beispiel ausgeprägte 
Migration und Phagozytose. Diese Veränderungen werden außerdem von modifizierten 
endogenen Proteinlevels von B-Raf, JNK1, MEK und ERM begleitet, was die Vermutung 
verstärkt, dass PI3K ein Regulator paralleler molekularer Signalwege, wie dem 
MAPK-Signalweg, ist. PI3K scheint die Sekretion von IL-10 und IL-12 nicht zu beeinflussen. 
PI3K scheint nur zu bestimmten Zeitfenstern relevant zu sein, statt während der gesamten 
Differenzierung. Diese Erkenntnisse erfordern weitere Untersuchungen in einer statistisch 
relevanten Studie. 
Die Effekte einer chemischen Inhibierung von ROCKII waren hauptsächlich bei Zytoskelett-
bezogenen Funktionen, wie Migration und Phagozytose feststellbar und wurden von 
Veränderungen in den endogenen ERM Proteinlevels begleitet. Außerdem beeinflusste die 
ROCKII Inhibierung die Levels von B-Raf und JNK1. Interessanterweise veränderte ROCKII 
die Sekretion von IL-10 und IL-12 dramatisch, ohne dabei das Potential eine T Zellantwort 
auszulösen zu verringern, was die Existenz eines alternativen, Interleukin-unabhängigen  
Mechanismus zur Aktivierung von T Zellen durch DCs nahe legt, möglicherweise durch 
direkten Kontakt dieser beider Zelltypen. ROCKII Inhibierung beeinflusste DCs am Meisten 
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durch die Erhöhung der Anzahl an Dendriten und durch die Verstärkung der Zelladherenz. 
Die Effekte von ROCKII auf die Expression von Reifungs-assoziierten Markern auf der 
Oberfläche von DCs waren gering, obwohl solche Ergebnisse weitere Untersuchungen in 
einer statistisch relevanten Studie benötigen. 
Obwohl einige Unterschiede in den Auswirkungen der chemischen Inhibierung von PI3K und 
ROCKII zwischen gesunden Kontrollen und Patienten gefunden wurden, sind weitere 
Untersuchungen notwendig um Individuums-spezifische Tendenzen auszuschließen. 
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4 INTRODUCTION 
4.1 The immune system 
The human immune system consists of three lines of defense against invading pathogens. At 
first, physical barriers prevent pathogens from entering the host. If pathogens overcome this 
barrier, the innate immune system provides an immediate but non-specific response. The third 
line of defense is the adaptive immune system which, upon activation by the innate immune 
system, attacks pathogens specifically and also possesses the ability to memorize a certain 
invader for future attacks. It consists of two components: the cell-mediated and humoral im-
munity. 
4.1.1 Dendritic cells play a pivotal role in immune surveillance 
Dendritic cells were first visualized in the skin by Paul Langerhans in 1868 and in response 
were called Langerhans cells, but their further characterization started not until the 70ies of 
the last century. Until that time, it was assumed that a proper immune response needs some 
kind of ‘accessory cells’ to trigger a proper primary antibody response in vitro, but first with 
the identification and purification from contaminating lymphocytes, their role as antigen-
presenting cells (APCs) became evident and further research was targeted upon them to iden-
tify their full spectrum of functions and effects. Until now, a broad understanding of dendritic 
cell biology has been unravelled and their pivotal role in the immune system slowly becomes 
clear, although there are still major questions unsolved and new arise every day. 
Some of their fundamental properties are as following: 
¾ Sentinels in vivo; in situ distribution to optimize antigen capture; migration 
into lymphoid organs to optimize clonal selection of rare CD4+ and CD8+ 
T cells 
¾ Initiators of immune responses: stimulation of quiescent, naïve and mem-
ory B and T lymphocytes 
¾ Potency in stimulating T cells: capacity of small numbers of DCs and low 
levels of antigen to induce strong T cell responses 
¾ Inducers of tolerance: deletion of self-reactive thymocytes, and anergy to 
mature T cells 
Table 1: Dendritic cells and the control of immunity (from Nature 392, 245-252 (1998)). 
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The ability to capture antigens, so-called ‘danger’ signals, which are subsequently processed 
and presented on the DC’s surface via MHC class I/class II molecules, and to migrate to 
draining lymph nodes, with the goal to induce a cellular and a humoral response or to induce 
tolerance respectively, entitles DCs to be useful in medical fields as cancer therapy, graft re-
jection or autoimmune disease.  
4.1.2 Subsets of DC: properties and development 
DCs are able to react upon different types of danger signals and to induce an appropriate im-
mune response. This is caused by different subtypes of dendritic cells with distinct properties 
and selective sensitivity to various antigens. The underlying mechanisms and the versatile 
lineage development are under investigation and so far crucial aspects have been discovered. 
Subtypes and plasticity 
It seems that two main pathways are the basement of DC differentiation1,2. The first is the 
myeloid pathway which generates two subsets, known as the Langerhans cells, predominately 
found in the skin, and the intestinal DCs, which distribute into all other tissues3. Secondly, the 
lymphoid pathway gives rise to plasmacytoid dendritic cells (pDCs), which characteristically 
secrete high levels of type I INFs upon viral infections4,5. 
Not only lineage segregation influences specificity of DCs, also the exposure to various cyto-
kines in vitro markedly alters phenotype and functions. Monocytes for example, can differen-
tiate in both, macrophages (G-CSF) and dendritic cells (GM-CSF) depending on cytokines 
encountered, and further in IL-4 DCs or INF-α DCs, if subsequently treated with IL-4 or 
INF-α6,7,8,9,10,11,12. These functional plasticity enables DCs to activate distinct immune re-
sponses corresponding to the encountered antigens although it has not yet become clear to 
which extent DC subsets or their plasticity determine a specific type of response. Monocyte-
derived DCs, activated with CD40L, respond in an IL-12-dependend mechanism to induce a 
TH1 response. In contrast, pDCs treated with IL-3 and CD40L prime a TH2 response secreting 
low amounts of IL-1213. A mixture of both, the type of DC subset and the cytokine signals 
encountered affects the polarization of T cells. 
Isolation of DC subtypes 
The investigation of DC subtypes has mostly not been performed by direct isolation of mature 
dendritic cells as their isolation and purification are difficult because the main available 
source for DCs is the blood. So, predominately pDCs and immature DCs have been isolated 
and further matured in culture. 
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Three different precursor-cell starting points are preferentially used to generate mDCs. The 
earliest precursor cells used are CD34+ fractions, isolated from bone marrow or umbili-
cal-cord blood, giving rise to Langerhans cells, intestinal DCs or DCs from CD34+ lymphoid 
precursors, depending on the combination of cytokines added14,15,16,17,18. 
The second and most commonly used precursor cells are isolated CD14+ peripheral-blood 
monocytes which are treated with GM-CSF and IL-4 to differentiate them towards immature 
dendritic cells. Finally, incubation with microbial products as LPS and Ribomunyl, or with 
proinflammatory cytokines as TNF-α produces fully mature DCs. 
The third precursors used, are interferon-α/β-producing plasmacytoid cells which are cultured 
with IL-3 and CD40L, or alternatively with microbial stimuli like the human herpes simplex 
virus19,20,21. 
DC properties 
Immature DCs are present in most tissues and scan their environment for ‘danger’ signals. 
They are able to perform phagocytosis, endocytosis and pinocytosis to capture invading 
pathogens such as bacteria and viruses, proteins, immune complexes and dead or dying cells. 
Further, iDCs possess a wide array of cell surface receptors to distinguish between the types 
of antigens, for cell-cell interactions and signalling respectively. These receptors originate 
from diverse receptor classes, as Integrins, C-type lectin-like receptors or Fc receptors. Anti-
gens recognized by an iDC, are processed, loaded onto MHC class molecules and presented 
on the cell surface. 
Upon antigen uptake and processing, iDCs become activated and undergo terminal differen-
tiation, which transforms them into cells specialized for T cell stimulation. The maturation 
process is characterized by an array of complex functional and phenotypical alterations. The 
potential of phagocytic uptake is strongly reduced, cytoplasmic extension, called dendrites, 
are formed, migration towards lymph nodes occurs and their potential to activate T cells is 
enhanced. Characteristic markers, including CD80, CD86, CD40, are higher expressed on the 
cell surface. Cytokines, including IL-12, are released to attract T and B cells and to skew an 
immune response into a specific direction22,23,24. 
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Interactions with T cells and its consequences 
mDCs which encounter naïve T cells in the lymph nodes, require three consecutive signals 
between T cells and mDCs to effectively prime an immune response. The first signal is 
through antigen presentation via MHC class I and class II molecules by which they can acti-
vate both, CD4+ and CD8+ T cells respectively. The second signal required, is interaction be-
tween CD80 and CD86 on the surface of DCs and CD28 on T cells. If this costimulatory sig-
nal is absent, T cells are tolerized. The third signal occurs through reciprocal interactions be-
tween CD40 on DCs and CD40L on T cells, priming IL-12 secretion by DCs25,26,27 which 
skews the immune system towards a TH1 response. The strength of the T cell response upon 
priming depends on various factors, like the state of DC maturation, the concentration of anti-
gen on the DC and the specific type of maturation stimulus28. If the T cell is effectively 
primed, it leads to clonal expansion and differentiation into memory cells and cyto-
kine-secreting effector cells to activate a full response. On the other side, improper activation 
due to diverse reasons, such as an immature state or profound expression of IL-10 can lead to 
the induction of tolerance through anergy of antigen-specific T cells, abortive proliferation or 
the induction of regulatory T cells29,30,31.  
4.2 Dendritic cells in cancer immunotherapy 
Dendritic cells are used as a relatively novel approach to vaccination against cancer. They are 
loaded ex vivo with tumor-associated antigens (TAA) and reintroduced into the patient to in-
duce tumor-specific killer and helper T cell responses directly in the patient. The ideal TAA 
would only be expressed in tumor cells and should be crucial for tumor growth and survival. 
4.2.1 Different approaches to initiate an immune response 
Several types of antigens and loading methods have been tried. The most common used strat-
egy is to load MHC class I and class II molecules with defined antigens32,33. But this tech-
nique has limitation like the restriction of the used peptide to a given HLA type or the limited 
number of well-characterized tumor-associated antigens. Further techniques employed are 
loading with total tumor lysate, recombinant proteins or exosomes, transducing DCs with vi-
ral vectors, transfection with DNA, RNA or plasmid DNA, targeting DCs with antibodies 
specific for DC cell surface molecules or loading with immune complexes. 
In this project, mRNA passive transfection is used to load iDCs with Survivin. This technique 
has some interesting advantages: mRNA is only transiently expressed in the target DCs and it 
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does not integrate into the host genome. Further, mRNA corresponding to gene products with 
known sequence can easily be generated in vitro by using appropriate primers and RT-PCR, 
which is coupled to a transcription reaction. The method is cost-effective and GMP-conform. 
There exist two possibilities, the amplification of whole-tumor mRNA and the amplification 
of defined genes, which are at best only expressed in tumors. Up to date, only a few genes, 
mostly fulfilling this criterion, could be identified, such as telomerase reverse transcriptase 
(TERT), oncofetal antigen (OFA), prostate-specific antigen (PSA), carcinoembryonic antigen 
(CEA) and Survivin34,35,36,37,38. Additionally, mRNA transfected DCs appear to be deficient in 
stimulating a CD4+ immune response, as transfected mRNA is preferentially channelled into 
the class I processing pathway activating CD8+ but not CD4+ T cells. 
 
Fig. 1: Generation and maturation of DCs in vitro (modified; J. Clin. Invest. 117, 1195-1203 (2007)). 
 
4.2.2 Survivin mRNA as tumor antigen 
Survivin mRNA, which is used to transfect DC in the experiments described in this thesis, has 
a restricted expression pattern, limited to embryonic and fetal development and is 
re-expressed in certain cancer cells at a frequency of 34-100%39,40, including ovarian, breast, 
prostate and colorectal cancer41. The expression in normal tissues seems to be very low or ab-
sent. Survivin functions as an inhibitor of apoptosis protein (IAP) and regulates cell cycle and 
apoptosis, increases tumor resistance to antiapoptotic stimuli, can block apoptosis and an-
tagonizing Survivin in tumor cells induces apoptosis42,43,44, which is further associated with 
resistance to chemotherapy45,46, increased rate of tumor recurrence47 and an enhanced prolif-
eration index48,49,50,51. Due to the strong effects upon tumor progression and its restricted ex-
pression, Survivin appears to be a promising target in cancer immunotherapy. 
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4.3 Cellular mechanisms regulate DC maturation 
The maturation process of dendritic cells is associated with fundamental alterations of mor-
phology, cytokine secretion, capability of antigen engulfment, migratory potential and marker 
expression. These characteristics are regulated by extracellular factors, depending upon 
strength, persistence and type of encountered signals, which subsequently alter intracellular 
signalling pathways. Recent studies revealed functional roles of members of the MAPK- and 
PI3K-pathway52, and RhoA and its downstream target ROCKII53 in the regulation of cellular 
processes associated with maturation. 
4.3.1 The involvement of PI3K-pathway in DC maturation 
Phosphoinosite-3-kinases (PI3K) are responsible for the phosphorylation of the D3 position of 
phosphatidyl inositols (PtdIns) family members, which are interacting with a high number of 
proteins via special binding domains. Three classes of PI3K have been identified so far de-
pending on their mechanism of activation and substrate specificity54. 
Class I PI3Ks are divided in two subgroups: Class IA PI3Kα, β and δ consist of a catalytic 
(p110) and an adaptor/regulator subunit (p85 family) associated in a heterodimeric fashion. 
Upon activation by tyrosine kinase receptors and G protein-coupled receptors (GPCR)55, the 
p85 subunit dissociates and localizes next to the plasma membrane in the proximity of its sub-
strate PtdIns56. Class IB PI3Kγ does not interact with p85 but with the p10157 and p84/87 
adaptor/regulators58,59 and is uniquely activated by GPCR60. The interaction of all class I 
PI3Ks with GTP-loaded Ras contributes to its activation61 and they all phosphorylate 
PtdIns(4,5)P2 (PIP2) to produce PtdIns(3,4,5)P3 (PIP3) to forward extracellular signals. 
Class II and class III PI3K are poorly characterized and they might be involved in vesicular 
trafficking62,63. Class II PI3K is probably involved in the production of PIP3 and PtdIns3P; 
class III PI3K produces PtdIns3P from PtdIns64. 
Class I PI3K activity influences a wide array of cellular functions because many proteins pos-
sess lipid-binding domains such as the pleckstrin homology (PH) domain. Important examples 
are PKB/Akt or phospholipase C (PLC) which bind PIP3 and PIP2 respectively. PKB/Akt is 
at the center stage of PI3K signalling and influences many fundamental cellular functions 
such as survival, proliferation, cell growth, protein synthesis and metabolism. In addition, 
most activators of small GTPases of the Rho family possess PH domains54, explaining the ef-
fects of PI3K on cytoskeletal remodelling, migration and membrane trafficking65 (Fig. 2). 
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Fig. 2: Schematic of multiple signalling through PI3K (Nat. Rev. Drug Discov. 5, 988-1004 (2005)). 
 
4.3.2 The RhoA-Rock-Ezrin-Pathway 
RhoA is a monomeric G protein and forms, together with Rac, CDC42 and about 20 other 
proteins the Rho GTPases, a subgroup of the Ras superfamily. Like all Ras-related proteins, 
RhoA cycles between an inactive GDP- and an active GTP-bound state66. Upon an upstream 
activation signal, RhoA releases GDP, facilitated by guanosine nucleotide exchange factors 
(GEFs), and binds GTP which sets RhoA to the active state. On the other side, 
GTPase-activating proteins (GAPs) significantly enhance the intrinsic GTPase activity of 
RhoA67,68, which leads to the hydrolysis of the bound GTP and returns RhoA into an inactive 
GDP-bound state. In addition, Rho GTPases are regulated by guanine nucleotide dissociation 
inhibitors (GDIs), which can inhibit hydrolysis of bound GTP and exchange of GTP69. Rho 
GTPases have been shown to play a crucial role in cellular processes such as cytoskeletal or-
ganization, cell growth, differentiation and apoptosis70,71. 
ROCKII is one of the best characterized downstream effectors of RhoA. Together with 
ROCK1, it forms the Rho-associated coiled-coil-containing protein kinase (ROCK) family. It 
consists of an amino-terminal coiled-coil domain, a central Rho-binding domain (RBD) and a 
carboxy-terminal PH domain. ROCKII also possesses an auto-inhibitory activity72, which can 
be disrupted by binding of RhoA73,74,75. Up to date, several substrates of ROCKII have been 
identified such as myosin light chain (MLC)76,77 stimulating actomyosin contractility78,79, 
REFERENCES 
 
 
14 
LIM kinases80,81,82 and ezrin/radixin/moesin83 modulating the actin skeleton and promoting 
apoptosis84, and PTEN85, which negatively regulates the PI3K-Akt pathway (Fig. 3). 
 
Fig. 3: The Rho-ROCK-pathway (from Nat. Rev. Mol. Cell Biol. 4, 446-456 (2003)). 
 
4.3.3 Kinase inhibitors abrogate phosphorylation of downstream targets 
As presented before; PI3K and ROCKII are essential for diverse cellular processes. The func-
tional inactivation of these proteins in the maturation of DCs possibly sheds light on their im-
portance in the production of fully mature dendritic cells, necessary for inducing a proper 
immune response in cancer immunotherapy. 
The method of choice is the use of synthetic inhibitors which abrogate the phosphorylation of 
PI3K and ROCKII respectively without inhibiting the proteins itself. 
PI3K inhibitors 
• Wortmannin is an antifungal antibiotic isolated from Penicillium funiculosum. It in-
hibits PI3K of all classes and further is a potent inhibitor of myosin light chain 
kinase86 and FMPL-stimulated processes87,88 (Fig. 4). 
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Fig. 4: chemical structure of Wortmannin. 
 
• LY294002 is a specific cell-permeable inhibitor against PI3K89 (Fig. 5). 
 
Fig. 5: chemical structure of LY294002. 
 
ROCKII inhibitor 
• Y27632 is a cell-permeable, potent inhibitor of both ROCK isoforms; ROCK1 and 
ROCKII. Studies suggest that it acts competitively with respect to ATP (Fig. 6). 
 
Fig. 6: chemical structure of Y27632. 
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5 MATERIAL AND METHODS 
5.1 Culture of dendritic cells 
5.1.1 Monocyte enrichment 
Peripheral blood mononuclear cells (PBMNCs) are obtained from cancer patients by leu-
kapheresis in an associated and certified center. The apheresate is immediately transported to 
CELL MED in an appropriate temperature-controlled box at 8°-20°C. It is eventually proc-
essed in order to gain an enriched phase of monocytes (mos) devoid of contaminating lym-
phocytes, erythrocytes and platelets. 
PBMNCs are also obtained from healthy volunteers. This is done directly at CELL MED by 
vein puncture using Heparin-Vacutainer tubes. The cells are processed in the same manner as 
the cells from patients to enrich the mos phase. 
The leukapheresate and whole blood are diluted in acid citrate dextrose solution 
(ACD; Baxter) 2.5 times, subsequently mixed with Ficoll (Biochrom) in a ratio of 1:1.5 and 
centrifuged for 20’ at 2000 rpm (break 0) at RT. In the next step the interface is collected with 
a pipette and further centrifuged twice for 10´ at 1200rpm at RT to enrich the mos. After 
counting the cells with an automatic cell counter (CASY-1®, Schärfe System GmbH), the 
pellets are resuspended in CellGro DC (CellGenix) for 2 hours at a final concentration of 
2x106 cells/mL and subsequently the non-adherent cells are washed out and the adherent are 
cultured as described underneath. The grade of purity is measured by FACS analysis of the 
markers CD14 and CD45; possible contaminations are detected by measuring CD3, CD16, 
CD19, CD41 and Glycophorine A (GPA) expression. 
5.1.2 Primary cell culture 
The mos are cultured for 5 days in ventable 50cm2 tissue culture flasks (Falcon®) at 37°C 
with 5% CO2. The medium, CellGro DC (CellGenix) supplemented with 2500U/mL GM-CSF 
(CellGenix) and 1000U/mL IL-4 (R&D), is used to induce the trans-differentiation to iDCs. 
Afterwards, the immature dendritic cells are loaded with human Survivin mRNA 
(150ng/107cells) for two hours, washed for 5 ´ at 1200 rpm, and finally matured in Cell-
Gro DC supplemented with 100µg/mL Ribomunyl (Pierre Fabre) and 1000µL/mL INF-γ 
(R&D) for 24 hours at 37°C with 5% CO2 saturation. The attachment to the plastic dish is a 
hallmark of mature dendritic cells. The non-adherent iDCs are washed away with the super-
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natant; the mDCs are detached by incubating the cells with Accutase (PAA Laboratories) for 
approximately 5 ´ at 37°C. The mDCs are centrifuged at 1200 rpm for 5 ´ at RT, then resus-
pended in RPMI (Gibco) supplemented with 2% FBS, and finally used for further experi-
ments. As an alternative, the dried pellets are resuspended in Glycerol sterile solution 
(Mayrhofer) and frozen at -80°C. 
5.2 Chemical inhibition 
The DCs are treated with the following chemical inhibitors:  
 40µM of ROCK inhibitor (Y27632; Biosource), 
 10µM of PI3K inhibitor (LY294002; Sigma), 
 10µM of PI3K inhibitor (Wortmannin W1628; Sigma), 
which are added at three different time points: either from the start of cell culture, before 
loading or before inducing DC maturation. If necessary, the inhibitors are replaced during cul-
tivation every 2nd day. 
5.3 Survivin mRNA preparation 
5.3.1 Cloning of Survivin DNA using Topo TA cloning kit (Invitrogen) 
TOPO TA cloning reaction 
0.5 to 4µL of TrueClone pCMV-DNA (100ng/µL), which contains the Survivin full-length 
cDNA (OriGene) is mixed with 1µL salt solution and the reaction is filled up to 5µL with wa-
ter. Finally, 1µL TOPO vector (Fig. 7) is added. The reaction is mixed gently and incubated 
for 5’ at RT. The incubation time can be extended from 30’’ to 3’ to reach a higher number of 
colonies, After the incubation, the reaction is placed on ice until transforming into one shot 
competent E. coli (Invitrogen) is performed. 
 
Fig. 7: pCR 2.1 TOPO cloning vector (Invitrogen). 
REFERENCES 
 
 
18 
Transformation of one shot competent E. coli 
E. coli bacteria are thawed on ice for 3’ for the transformation. Then 2µL of the TOPO TA 
cloning reaction are added and incubated for 5’-30’. Next, a heat shock for 30’’ at 42°C is 
performed and 250µL of SOC medium (Invitrogen) are added at RT. The transformed cells 
are incubated for 1 h at 37°C and 250µL from the transformation is spread on pre-warmed LB 
agar plates, containing Ampicillin in a concentration of 100µg/mL. Plates are incubated at 
maximum for 18 hours at 37°C and checked for positive clones. 
Liquid culture 
Each clone is transferred to a sterile tube containing 3mL of LB liquid media, supplemented 
with Ampicillin. The liquid culture is incubated overnight at 37°C on an orbital shaker at 
200 rpm. 
Reagents 
LB agar + Ampicillin plates 
 25g LB medium (MP Biomedicals) 
 15g Agar agar (Carl Roth GmbH) 
The final volume is adjusted to 1L with water. The solution is autoclaved for 15’-20’ and 
cooled down to 50°C. Finally, it is added up with 100mg Ampicillin (Sigma). 
LB liquid media 
 10g/L Tryptone (MP Biomedicals) 
 g/L Yeast Extract (MP Biomedicals) 
 10 g/L NaCl (Merck) 
Finally, the pH is adjusted to 7.0 with 1N NaOH. 
The final solution is autoclaved. 
5.3.2 Plasmid isolation using Qiagen® plasmid isolation kit 
1.5mL of the cell suspension are transferred to a 2mL tube and centrifuged for 5’ at 
10,000 rpm. Then the supernatant is discarded and the rest of the E. coli suspension is pipet-
ted into the tube containing the bacteria pellet. This is again centrifuged under the same con-
ditions.  
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The Kit contains Rnase A, which has to be dissolved in buffer P1. Each pellet is completely 
resuspended in 300µL of buffer P1. This lysing step is the crucial step in the procedure. Af-
terwards, 300µL lysis buffer P2 are added and mixed by inverting the tube several times fol-
lowed by an incubation step for 5’ at RT. This step is required to grant the degradation of ge-
nomic DNA of bacterial origin.  
300µL pre-cooled neutralization buffer P3 are added to the tube after 5’ and mixed again by 
inverting the tube several times before performing an incubation step of 5’ on ice. The pre-
cipitation step is accelerated by the low temperature. Samples are centrifuged at 12,000 rpm 
for 10’ to remove cell debris.  
In the meantime, the Qiagen tips are equilibrated. Shortly, 1mL equilibration buffer QBT is 
loaded on each column, let be flown through completely and dried at RT. After centrifuga-
tion, the clear supernatant containing the plasmid-DNA is collected and transferred to the 
Qiagen tips. The solution enters the column and after the whole supernatant is flown through 
it, the plasmid-DNA, which has been bound by the resin instead, is washed twice with 1mL of 
QC buffer. 
After the washing step, the plasmid-DNA is eluted with QF buffer. Shortly, a fresh 1.5mL 
tube is positioned under the column and 800µL QF buffer are pipetted to each column. 560µL 
isopropanol (7 times volume) are added to the eluted plasmid-DNA and mixed by inverting 
the tube. Afterwards, a centrifugation step at 12,000 rpm for 30’ is performed at RT. It is im-
portant to collect the DNA at RT because at lower temperature salts can also be collected and 
can therefore contaminate the DNA. The supernatant is discarded and 1mL ethanol (70%) is 
added to each DNA-pellet before performing a second centrifugation step for 7’ at 
10,000 rpm. This procedure is repeated twice. Then the pellet is air-dried for 5’ at RT and dis-
solved in 100µL 1xTE buffer. The plasmid DNA is stored at -20°C until further use. 
5.3.3 Transcription of Survivin from a miniprep-sample 
pCMV-Survivin linearization from Miniprep 
5µg plasmid is digested with XbaI (Fermentas). Shortly, the plasmid DNA is diluted in water 
to obtain a final concentration of 5µg plasmid in 50µL volume. Next, 15µL of 10x buffer 
Tango (Fermentas) and 30 units XbaI restriction enzyme are added and the reaction is filled 
up to 153µL with water. The linearization is performed for 2 hours at 37°C. Subsequently, the 
reaction is stopped and the cDNA is precipitated by adding 1/20 EDTA (0.5M; Pharmacia 
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Biotech), 1/10 Sodium acetate (3M; Sigma) and 2 volumes of ethanol (100%; Merck). The 
reaction is incubated for 15’ at -20°C and afterwards centrifuged for 15’ at top speed. Finally, 
the supernatant is removed and the tube is re-spinned. The residual supernatant is removed 
with a fine-tipped pipette and the pellet is resuspended in 45µL water. 
Proteinase K treatment 
SDS (Sigma) is added to a final concentration of 0.5% and proteinase K (1mg/mL; Roche) is 
added to the linearized cDNA to a final concentration of 200µg/mL. The sample is thereafter 
incubated for 30’ at 50°C. 
Phenol/Chloroform extraction 
DNA sample is added up to 100µL with water. Further 50µL phenol (Fluka) and 
50µL chloroform (Fluka) are added. The sample is mixed and centrifuged for 3’ at top speed. 
The aqueous phase is transferred into a fresh tube and centrifuged for 3’ at top speed to re-
move the remaining phenol. Next, the aqueous phase is again transferred into a fresh tube and 
the equal volume of chloroform is added, centrifuged for 3’ at high speed and again the aque-
ous phase is transferred into a fresh tube. 
1/20 volume of EDTA (0.5M; Pharmacia biotech), 1/10 volume of sodium acetate (3M; 
Sigma) and 2 volumes of ethanol (100%; Merck) are added to the extracted DNA to 
precipitate the DNA. The reagents are mixed with the sample and incubated for 15’-20’ at 
-20°C. The supernatant is carefully removed and 700µL ethanol (70%; Merck) are added to 
wash the precipitate, followed by a centrifugation step for 10’ at top speed. The supernatant is 
removed with a fine-tipped pipette and 10µL water is added to the air-dried pellet. The 
concentration is determined by using a photometer (Peqlab). 
Transcription reaction 
For the transcription reaction the reagents included in the mMessage mMachine kit (Ambion) 
are thawed. 10µL 2x NTP/CAP are mixed with 2µL 10x reaction buffer, 2µl enzyme mix and 
1µg linearized cDNA template and the reaction is filled up to a final volume of 20µL with 
nuclease-free water. The reaction is mixed by short centrifugation and incubated for 2 hours 
at 37°C. Afterwards, 1µL TURBO DNase is added, mixed well and incubated for 15’ at 37°C. 
Cleaning and recovery of RNA 
The contents of the MEGAclear kit (Ambion) are warmed to RT. The volume of the RNA 
sample is adjusted to 100µL with elution solution and mixed gently. 350µL binding solution 
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concentrate are added and the reagents are mixed by pipetting. In the next step, 250µL ethanol 
(100%; Merck) are added and again mixed by pipetting. The RNA mixture is then applied 
onto a filter cartridge and centrifuged for 1’ at 10,000g. Afterwards, the flow through is dis-
carded and the filter cartridge is washed twice with 500µL washing solution, containing etha-
nol. Next, the RNA is diluted with 50µL water. Therefore, the filter cartridge is placed into a 
new collection tube and 50µL water is applied to the center of the filter, the cap is closed and 
the tube is incubated for 5’-10’ at 65°C. The RNA is recovered by centrifugation for 1’ at RT. 
The elution procedure is repeated with 50µL water to maximize the RNA recovery. The RNA 
yield is determined by using a photometer and the quality is checked by real-time RT-PCR. 
5.4 Analysis of the cells 
5.4.1 Morphology 
An inverted microscope (Axiovert; Zeiss) and a digital photo camera (Axiocam; Zeiss) with 
the appropriate software (Axiovision; Zeiss) are used to take pictures for subsequent analysis 
of the morphology of the cell before the cells are harvested after maturation. The following 
settings are preset: 40x magnification and 20’’ exposure time. 
5.4.2 Phenotype (FACS) 
Three aliquots of 106 cells each are necessary for this analysis. Each aliquot is resuspended in 
50µL of the appropriate mix of antibodies or isotype controls, diluted in PBS, supplemented 
with 1% BSA and 0.1% NaN3, and incubated in the dark for 15´ at RT. The cells are washed 
in 1.5 mL PBS at 800 rpm at RT and finally resuspended in 0.5 mL staining buffer to measure 
the signal strength with a FACS device (Beckmann Coulter). 
As mentioned before, the mos are enriched by Ficoll purification. FACS analysis is used to 
measure the concentration of the mos obtained. The following markers are analysed: 
Antibody Fluorescence dye Company 
CD14 FITC Beckmann Coulter 
CD45 PC7 Beckmann Coulter 
Table 2: FACS antibodies against mos. 
Leukocytes, erythrocytes, platelets and granulocytes can still be present as contaminants after 
Ficoll purification. So, the cell suspensions are analysed via FACS to determine the level of 
the following CD markers: 
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Antibody Fluorescence dye Expressed on Company 
CD3 PC5 T-cells Beckmann Coulter 
CD16 PC5 Granulocytes Beckmann Coulter 
CD19 PE B-cells Beckmann Coulter 
CD41 FITC Platelets Beckmann Coulter 
Glycophorine A PE Erythrocytes Beckmann Coulter 
Table 3: FACS antibodies used to determine contaminating cells. 
At last, the maturation stage of the dendritic cells is measured at two distinct time points: after 
5 days of trans-differentiation and after 24 hours of maturation, respectively. The expression 
of the following markers is analysed: 
Antibody Fluorescence dye Company 
CD40 PC5 Beckmann Coulter 
CXCR4 PE Becton Dickinson 
CD80 FITC Beckmann Coulter 
CD83 PC5 Beckmann Coulter 
CCR5 FITC Becton Dickinson 
HLA-DR PC5 Beckmann Coulter 
CCR4 PE Becton Dickinson 
Table 4: FACS antibodies used to determine maturation stage. 
5.4.3 ELISA (IL-10 and IL-12 secretion) 
IL-10 and IL-12p70 secretion into the supernatant is measured after trans-differentiation and 
maturation, respectively, following the OptEIA ELISA sets protocol (BD Pharmington). At 
first the required wells are coated with IL-10 or IL-12p70 antibody, diluted in coating buffer 
as recommended in the lot-specific analysis certificate, and incubated at 4°C overnight. The 
next day, the plate is washed thrice and 200µL of the supplied assay diluent are added for 1h 
incubation at RT. After successive washing for three times, 100µL of 1:2 diluted samples and 
100µL of each standard are filled into the wells in duplicate and incubated for 2h at RT. The 
samples are washed 5 times, 100µL of working detector reagent (consists of diluted, bioti-
nylated IL-10 and IL-12p70 detection antibody and streptavidin horseradish peroxidase) are 
added for 30´ followed by 7 times washing with a soaking time of one minute per washing. 
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100µL of substrate solution are added and the wells are kept in a dark room for 30’. Finally, 
50µL stop solution is pipetted into the wells and within 30’ the plate is read out with a pho-
tometer (BioRad) at 450nm with a wavelength correction at 570nm. The measured absorb-
ance directly relates to the detected interleukins and corresponds to the standard dilution. 
5.4.4 Proliferation assay (mixed leukocyte reaction) 
Dendritic cells (at a final concentration of 1x106 cells/well) are co-cultured with the non-
adherent fraction of Ficoll-separated PBMNCs from a healthy donor (1x104 cells/well) diluted 
in RPMI with 2% FBS (Gibco) supplemented with 10%  AlamarBlue® in a 96-well U-bottom 
plate at a final volume of 150µL/well. AlamarBlue® changes from its oxidized (blue) to the 
reduced form (red). The absorbance is measured with a plate reader (SLT-Tecan) at 595nm 
with a reference wavelength at 620nm every 4-12h over a period of 2-7 days. 
5.4.5 Phagocytosis assay (FITC-dextran uptake) 
Three aliquots of each sample, with 1x106 cells per aliquot, are resuspended in 1.5mL 
RPMI 1640 (Gibco), admixed with 2% FBS, in a 6-well plate. Two aliquots (spontaneous and 
induced phagocytosis) are supplemented with 0.5µg/ml FITC-dextran. 300ng/mL CCL19 
(Sigma) are further added to one of them to induce phagocytosis. The cells are incubated for 
2 hours at 37°C, washed twice in cold PBS and centrifuged for 5’ at 1200 rpm at RT. Thereaf-
ter, the cells are resuspended in 0.5mL cold PBS and their phagocytic activity is measured 
with a FACS® device (Becton Dickinson). 
5.4.6 Migration assay (Transwell assay) 
3 wells of a 6-well plate are used for each sample. 1.5mL RPMI 1640 (Gibco), mixed with 
2% FBS, are filled into the lower part of the well. 300ng/mL CCL19 are added to the third 
well to induce migration. In the next steps, the filter is inserted, 500µL of cell suspension 
(1x106 cells) are pipetted into the well and the plate is incubated for 2h at 37°C with 5% CO2 
saturation. The incubation is stopped by adding 1.5mL 8% paraformaldehyde (PFA, Sigma) 
to the lower part of the well, respectively 500µL to the upper part at a final concentration of 
4% PFA, for 10’ at RT. Afterwards, the wells are washed once with PBS. 
In the next step, the upper surface of the filter of the second and third well is scraped with a 
cotton-tipped swab and the remaining cells are stained with a 0.2% crystal violet (Sigma) in 
20% methanol (Merck) solution for 5’ at RT. The filters are rinsed with water to remove ex-
REFERENCES 
 
 
24 
cess staining solution and are air-dried. Finally, the membranes are cut out with a scalpel, 
mounted on a glass slide with Entellan (Merck) and photographed for successive counting. 
5.4.7 Viability assay 
1x105 cells are resuspended in 500µL binding buffer following the Annexin V FITC apoptosis 
detection kit (Biovision). Then, the suspension is incubated with 5µL Annexin V FITC and 
5µL propidium iodide (PI) for 5’ at RT in a dark room. Annexin V binding is measured by 
flow cytometry using FITC signal detector, PI staining with the phycoerythrin emission signal 
detector. 
5.4.8 Western blot 
Protein extraction 
All steps are performed on ice to avoid protein degradation. 2x106 cells are thawed in 100µL 
Frackelton buffer (Table 5, 6), vortexed and incubated at 4°C for 20’ to gain cytoplasmatic 
proteins. After further vortexing, the cells are centrifuged for 20’ at 4°C at 14000 rpm. So, the 
pellet (nuclear) and supernatant (cytoplasmatic) are separated from each other. 100µL of the 
supernatant are resuspended in 25µL 5x SDS sample buffer with 100mM DTT and stored at 
-20°C. The samples are heated up to 75°C before being loaded on the SDS-Page gel. 
Reagents 
Frackelton Buffer 
Component Stock solution Amount added 
Tris-Cl 10mM 0.24g 
Na4P207 30mM 2.7g 
NaCl 30mM 0.6g 
Triton 100x  2mL 
MilliQ water  Fill up to 200mL 
Table 5: Frackelton buffer stock solution components. 
stored at +4°C 
 
 
 
REFERENCES 
 
 
25 
Added just before use: 
Component Stock solution Final concentration Dilution fV = 1.2mL Frackelton Buffer 
NaF 1M 50mM 1:20 60µL 
Na3VO4 100mM 0.1mM 1:1000 1.2µL 
Protease 
Inhibitor 
cocktail 
  1:25 48µL 
OA 100mM 0.1mM 1:1000 1.2µL 
PMSF 0.1M 1mM 1:100 12µL 
Table 6: Frackelton buffer components. 
 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-Page gel is prepared as following described: 
Two clean glass-plates and two clean spacers are used to prepare a gel chamber, which is in-
serted into a casting module (BioRad). A solution of 10% polyacrylamide separating gel (Ta-
ble 7) is prepared and poured into the chamber with a pipette to fill approximately 75% of the 
chamber. The gel is covered with isopropanol and let polymerise for 5’ at RT. Isopropanol is 
discarded after polymerisation and the 4% polyacrylamide stacking gel solution (Table 8) is 
poured on the top of the separating gel; finally a comb is inserted in the stacking gel that is let 
polymerise for 10’. 
Running gel 10% 1 small gel 
Tris-Cl, pH8.8 1.5M 3mL 
Bis/Acrylamide 30% (Biorad) 4mL 
SDS 20% 60µL 
milliQ water 5mL 
APS 10% (Sigma) 48µL 
TEMED (Sigma) 24µL 
Table 7: SDS-page 10% running gel. 
 
 
REFERENCES 
 
 
26 
 
Stacking gel 10%  
Tris-Cl, pH6.8 1.5M 1mL 
Bis/Acrylamide 30% 0.5mL 
SDS 20% (Sigma) 20µL 
milliQ water 1.25mL 
APS 10% 24µL 
TEMED 12µL 
Table 8: SDS-page stacking gel. 
After removing the comb, the slots are filled with milliQ water and the gel is inserted in the 
electrophoresis chamber that is in turn filled with the running buffer. Finally 5µL of the 
marker (prestained SDS PAGE standard; Fermentas) and a volume corresponding to 5µg of 
each sample are loaded. The electrophoresis is performed for approximately 75’ at 160V. 
Immunoblot and Ponceau Red staining 
After SDS-PAGE, the proteins are transferred from the PAA gel to a nitrocellulose membrane 
in 1x transfer buffer for 1h at 30V in a semi-dry blotting apparatus (Mini-PROTEAN Tetra 
system; Bio-Rad). The immunoblotting sandwich is made up of two pre-wetted filter papers, 
cut to reach the size of the gel, the previously pre-equilibrated membrane, the gel, and further 
two pre-wetted filter papers. The sandwich is placed in a way that the gel is at the cathode and 
the membrane at the anode. 
After the transfer, the membrane is stained with Ponceau Red in order to determine the quality 
of the blotting. Afterwards, the membrane is rinsed once in water and washed with TTBS un-
til all the red staining is completely removed. 
Reagents 
 10% APS: 1g ammonium persulphate (Sigma) dissolved in 10mL milliQ water; 4°C. 
 Ponceau Red 10x (stock solution): 2g Ponceau S (Serva), 30g trichloracetic acid 
(Merck), 30g sulphoalocyclic acid (Merck), MilliQ water to 100mL. 
 10x Running buffer: 0.25M Tris (Sigma), 1.92M glycine (Fluka), milliQ water to 1L. 
 Separation gel buffer (pH 8.8): 1.5M Tris-Cl, 0.4% SDS, milliQ water to 1L. 
 Stacking gel buffer (pH 6.8): 0.5M Tris-Cl, 0.4% SDS (Sigma), milliQ water to 1L. 
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 10x Blotting buffer: 29g glycine (Merck), 58g Tris-Base, 3.7g SDS, water to 1L; 4°C. 
 1x Blotting buffer: 10% 10X Blotting buffer, 20% methanol, milliQ water to 1L. 
 10x TBS: 250mM Tris-Base, 1.5M NaCl (Merck); pH 8.0, milliQ water to 1L. 
 TTBS: 100mL 10x TBS, 500µL Tween-20 (Promega), milliQ water to 1L; 4°C. 
 
Incubation with the antibodies 
Non-specific binding is blocked by incubating the membrane one hour in a solution of TTBS 
added up with 5% powder milk. Thereafter, the membrane is washed twice with TTBS for 
10’. Finally it is incubated overnight with the appropriate primary antibody (Table 9) diluted 
in TTBS and 0.1mM NaN3. 
1st antibody Company Dilution 2nd antibody 
Actin Santa Cruz 1:1000 Goat 
Ezrin/Moesin/Radixin Cell Signaling 1:1000 Rabbit 
pEzrin/pMoesin/pRadixin Cell Signaling 1:1000 Rabbit 
B-Raf C-terminal Santa Cruz 1:500 Rabbit 
B-Raf N-terminal Santa Cruz 1:500 Rabbit 
C-Raf BD Transduction Laboratories 1:1000 Mouse 
MEK1/2 Cell Signaling 1:500 Rabbit 
pMEK Cell Signaling 1:500 Rabbit 
p38 Santa Cruz 1:500 Rabbit 
pp38 Santa Cruz 1:200 Rabbit 
pJNK Cell Signaling 1:500 Rabbit 
JNK Cell Signaling 1:500 Rabbit 
Table 9: Western blot antibodies used against specific endogenous proteins. 
The day after, the membrane is washed three times for 10’ in TTBS and subsequently incu-
bated for 30’ with the appropriate secondary antibody, diluted in TTBS. 
Thereafter, the membrane is washed three times with TTBS for about 30’ and finally rinsed in 
TTBS. 
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ECL detection 
After the incubation with the primary and the secondary antibody, the membrane is incubated 
with 0.5mL of previously mixed Luminol/Enhancer Solution and Stable Peroxyde-Solution 
(Pierce) for 5’. The excess of the detection buffer is removed; the membrane is positioned be-
tween two clean transparent papers and thereafter placed in a film cassette. Finally, it is ex-
posed to an ECL-hyperfilm (Amersham) in the dark room for a time comprised between 10’’ 
and 1h, depending on the strength of the signal. 
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6 RESULTS 
Dendritic cells were either obtained from whole blood of healthy volunteers or from surplus 
of leukaphereses of cancer patients (Table 10). Quantitative limitations made it impossible to 
perform all experiments with the same patients. 
Name sex Age [years] Cancer type 
Patient A male 52 Colon 
Patient B female 50 Breast 
Patient C female 59 Ovarian 
Patient D female 51 Breast 
Patient E female 47 Ovarian 
Control 1 female 30 - 
Control 2 female 29 - 
Control 3 female 34 - 
Control 4 female 24 - 
Control 5 female 36 - 
Control 6 male 23 - 
Table 10: Cancer patients and healthy volunteers. 
 
6.1 Morphology 
In the first step, the morphology of non- and inhibitor-treated cells was analysed by light mi-
croscopy to assess the effects caused by LY294002, Wortmannin and Y27632 upon adher-
ence, shape and viability (Fig. 8). 
Dendritic cells derived from Patient B upon loading and maturation became adherent and 
formed big clusters. On the contrary, dendritic cells from the same patients but treated from 
the start with LY294002 or Wortmannin tended to remain in the supernatant and did not ag-
gregate. Cells treated with Wortmannin showed an even less trend towards adherence than 
cells treated with LY294002. Cell treated with Y27632 showed a combined phenotype of star-
shaped and strongly adherent cells and clusters of round cells, which tended to slightly adhere 
to the flask surface.  
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Control LY W Y  
Fig. 8: DC morphology of untreated control and upon treatment with selective inhibitors from the start 
of culture. 
 
6.2 Phenotype (FACS)  
Since the addition of selective PI3K as well as ROCK inhibitors significantly modified the 
normal phenotype of mature DCs, we further investigated whether such a difference corre-
lates as well with a modification in the expression of surface markers, which are known to be 
increased during human DCs maturation. Shortly, we analysed by FACS DCs derived either 
from healthy controls or patients for the following markers: CD80, CD83, CD40, CXCR4, 
CCR5, CCR4, HLA-DR and CD95L after the first 5 days of culture in presence of IL-4 and 
GM-CSF (iDCs) and 24h after loading and maturation (mDCs). 
6.2.1 Addition of PI3K and ROCK inhibitors from start 
The analysis of the phenotype was performed with a healthy control (Control 1) and a patient 
suffering from colon cancer (patient A). In this setting, the inhibitors were added at the start 
of cell culture and the expression of relevant surface markers was measured after 5 days 
(iDC), and after further 24 h of maturation mDC), respectively. 
Immature DCs 
Untreated cells derived from the healthy control showed high surface expression of HLA-DR 
and CD40, mild expression of CD80 and low CXCR4 expression. The other analyzed markers 
were almost absent on iDC surface. In comparison, immature DCs derived from the patient 
displayed a high HLA-DR expression, although not reaching the levels observed on iDCs de-
rived from the healthy control; a mild-low expression of CD40, CXCR4, CD80, CCR5, CCR4 
and CD95L, while CD83 was almost undetectable.  
Addition of the PI3K inhibitor LY294002 did not affect the expression of CD40, CD83, 
CCR4 and HLA-DR on iDCs derived both from the healthy control and the patient; it slightly 
decreased the expression of CD80 on healthy control derived iDCs and strongly the expres-
sion of CD80 on patient derived iDCs. It almost did not affect CCR4 expression on healthy 
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control derived iDCs and slightly increased the expression of such a marker on patient derived 
iDCs. It did not affect CCR5 and CD95L expression on healthy control derived iDCs while 
strongly decreasing the expression of such a marker on patient derived iDCs.  
Wortmannin addition caused different effects on iDCs phenotype in comparison to those ob-
served upon LY294002 addition, suggesting that these two inhibitors affect parts of the PI3K 
pathway, which are pivotal for different aspects of the DC phenotype that are strongly af-
fected upon cancer development as well. Indeed, upon Wortmannin addition, CD40 and 
HLA-DR expression were strongly down-regulated on healthy control derived iDCs but not 
on patient derived iDCs. Such an inhibitor strongly impaired the expression of CXCR4 and 
CD80 on healthy control only and on healthy control as well as patient derived iDCs, respec-
tively. It did not affect the expression (already very low) of CD83, CCR5, CCR4 and CD95L 
on healthy control derived iDCs, while strongly increasing CXCR4 and CD83 expression and 
strongly decreasing the expression of CCR5 and CD95L on patient derived iDCs.  
Inhibition of the Rho-associated kinase with Y27632 had minor effects on any analysed 
markers regarding iDCs derived from healthy control. On the contrary such an inhibitor 
strongly decreased the expression of CD80, CCR5, CCR4 and CD95L and mildly that of 
HLA-DR on iDCs derived from patient. These findings suggest that ROCK function on hu-
man DCs may be affected by tumor development. 
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Fig. 9: Marker expression profile of iDCs of control 1 and patient A inhibited from start. 
 
Mature DCs 
After 5 days in culture, cells were loaded with Survivin by passive transfection (6h) and after 
maturation for 24h upon addition of the maturing cocktail, fully mature cells were harvested 
and tested for surface markers expression. 
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As expected, the expression of surface markers of both healthy control and patient derived 
mDCs, increased markedly upon maturation. Anyhow, the expression of CD83 was strongly 
reduced in mDCs derived from patient in comparison to that observed on healthy control de-
rived mDCs. 
Upon addition of LY294002 the expression of CXCR4, CCR4 and CD83 was slightly de-
creased while that of CCR5 and CD95L was strongly decreased on mDCs derived from 
healthy control. Differently, mDCs derived from patient showed a very strong impairment of 
the expression of all the analysed markers beside CD83 upon incubation with LY294002. 
Such results showed that the DC response to LY294002 is affected by the tumor. Indeed the 
PI3K pathway sensible to LY294002 seems to be more important for the establishment of the 
right phenotype of the mDCs in patient- in comparison to healthy control derived DCs. 
Wortmannin addition strongly decreased the expression of all analysed markers on mDCs de-
rived from healthy control, showing a more powerful effect on such DCs in comparison to 
LY294002. A strong impairment of CD40, CD80, CCR5, CCR4 and CD95L was detectable 
on mDCs derived from patient as well. In this case, anyhow, Wortmannin has only a mild 
down-regulative effect on the expression of CXCR4 and HLA-DR while slightly increasing 
the expression of CD83. Interestingly, the effects of Wortmannin on CXCR4 and HLA-DR 
expression were far weaker than those caused by the addition of LY294002. These results 
seem to suggest that Wortmannin effects are more important in healthy control derived DCs 
while LY294002 effects mostly interest patient derived DCs, possibly supporting the idea that 
tumor development causes a modification of the PI3K pathway involved in the phenotypical 
maturation of human DCs. More experiments in this direction are required to confirm or con-
fute such a theory.  
ROCK inhibition did not affect the surface markers expression on mDCs derived from 
healthy control and mildly affected that of CD80, CCR5, HLA-DR and CD95L on patient de-
rived mDCs. The strongest effect was detectable regarding CCR4 expression on patient de-
rived mDCs. In this case, too, ROCK pathway seems to be more related to the establishment 
of the right phenotype in mDCs derived from patients than in those derived from healthy con-
trols, suggesting a possible correlation between ROCK function and tumor progression, re-
garding human DC phenotype. 
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Fig. 10: Marker expression profile of mDCs of control 1 and patient A inhibited from start. 
 
6.2.2 Addition of PI3K and ROCK inhibitors from loading 
LY294002 treatment markedly lowered the expression of all markers of the healthy control 
besides CCR4, which was slightly up regulated, compared to the cells treated from the very 
start of culture. The patient’s derived DC showed only reduction in CXCR4 expression and a 
higher expression level of CCR4 and HLA-DR. The strongest differences could be seen upon 
direct comparison between Control 1 and Patient A. Here, patient’s derived DCs expressed 
lower levels of CD40, CD80 and CCR4 and higher levels of CD83 and HLA-DR. The pro-
duction of CXCR4, CCR5 and CD95L was almost completely abrogated. LY294002 nega-
tively influences the expression of maturity-associated markers, especially in the healthy con-
trol, the only exception being CCR4. These results give a primary indication of a crucial role 
of PI3K at least regarding the phenotypical maturation of human DCs. 
The effects of incubation with Wortmannin significantly differed from those observed from 
the very start of culture in the healthy control and from the effects of LY. The expression, es-
pecially of CD40, CXCR4, CD83, HLA-DR and CCR4, was profoundly increased. Differ-
ently, patient’s derived mDC did not reflect the same results. CD80, CCR5, HLA-DR, CCR4 
and CD95L levels were comparable to those after inhibition from the start; only CD40 and 
CD83 were up-regulated and CXCR4 expression was actually diminished. Further comparing 
the healthy control with the patient showed almost completely identical expression levels of 
all markers. Wortmannin inhibition reflects the findings of LY, as marker expression de-
creased in comparison to untreated cells, denoting PI3K as promoter of phenotypical matura-
tion. More controversial are the findings concerning exposure time, as a long exposure time 
enhances effects of LY in the healthy controls but not in the patients. 
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ROCK inhibition slightly reduced CD40, CD80 and CCR5 expression in the healthy control, 
respectively CD83 and HLA-DR more profoundly relative to the inhibition from start. 
CXCR4 and CCR5 expression levels were increased whereas CD95L remained stable. In the 
patient, the levels of CD40, CCR4 and CD95L were unaffected by the different time points of 
inhibition but CXCR4, CD80, CD83, CCR5 and HLA-DR showed reduced expression. Pa-
tient and control presented distinct differences if marker expression was analysed upon 
ROCK inhibition. So, only CD95L was expressed at the same level as in Control 1, the re-
maining markers were down-regulated in patient’s derived DCs. ROCK inhibition decreased 
marker expression more strongly, if administered at a later time point and seemed to have a 
higher impact upon the phenotype of patient’s derived DCs. The influence of ROCK, al-
though significant, is not as pronounced as that of PI3K inhibitors. 
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Fig. 11: Marker expression profile of mDCs of control 1 and patient A inhibited from loading. 
 
6.2.3 Addition of PI3K and ROCK inhibitors from maturation 
Upon PI3K inhibition with LY294002 significant differences could be observed between in-
hibition from maturation and from earlier time points in the healthy control. The expression of 
CXCR4, CCR5 and CD95L was decreased and the expression of the other markers levelled 
between or at the level of former time points. In the patient’s derived DCs the expression lev-
els of the investigated markers were more similar to those from earlier time points, although 
CD40, CD80 and CD83 were higher and HLA-DR lower expressed. Direct comparison be-
tween control’s and patient’s derived DCs could not elicit any greater differences in any of 
the markers. In conclusion, the presented results show that LY negatively influences the ex-
pression of surface markers and denote PI3K as crucial in maintaining phenotypical matura-
tion. 
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Incubation with Wortmannin increased the expression of every marker in the healthy control 
similarly to inhibition from start, which reflected the same results obtained upon inhibition 
from loading besides a slight enhancement in production of CXCR4 and HLA-DR as well as 
a minor reduction in CD95L expression. These similarities could also be observed between 
Control 1 and Patient A, where all markers were expressed equally. Concerning Patient A, in 
comparison with inhibition from the loading, Wortmannin had the highest impact upon sur-
face marker expression especially if administered from the very start of cell culture apart from 
a reduction in CD95L production. Interestingly, the effects of Wortmannin were partially dif-
ferent to those of LY, which might be caused by the different pathways, which are selectively 
blocked by each of the two PI3K inhibitors.  
Finally, ROCK inhibitor Y27632 strongly reduced the expression of CXCR4 and CD80, im-
paired CCR5 production, slightly diminished the expression of CD83 and CCR4 and only in-
creased the level of HLA-DR in the healthy control regarding inhibition from loading. In 
comparison, the markers in Patient A were almost equally expressed with a slight increase in 
HLA-DR, CCR4 and CD95L production but not in parallel with earlier time points of inhibi-
tor addition, where CD40, HLA-DR, CCR4 and CD95L levels were up regulated, CCR5 pro-
duction impaired and CD83 decreased. Taken together, the effects of ROCK seem to be 
smaller than those of PI3K with the exception of CD83, which was down to a basal level in 
mature DCs in five of six cases. The time of inhibitor administration appears not to be crucial 
for optimal effects.  
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Fig. 12: Marker expression profile of mDCs of control 1 and patient A inhibited from maturation. 
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6.3 ELISA (IL-10 and IL-12 secretion) 
6.3.1 Addition of PI3K and ROCK inhibitors from start 
Since our preliminary experiments about the effects of PI3K and ROCK inhibition upon the 
morphology and the phenotype of DCs during their maturation showed that indeed, such 
pathways play crucial roles, we further investigated whether these phenotypical effects mir-
rored functional consequences as well. 
IL-10 expression correlates with the induction of a tolerogenic environment, which strongly 
impairs the maturation of human DCs. Such IL is normally expressed at very low levels by in 
vitro cultured iDCs. On the contrary, IL-12 is highly secreted by mDCs according to their 
maturation stage and it increases the CTL response. 
Immature DCs 
The secretion levels of IL-10 and IL-12 in untreated iDCs were according to the literature re-
ports, as expected. IL-12 was not produced by any of the samples and IL-10 only slightly in 
two controls. This reflects the immature state of the DCs, proper in vitro conditions and re-
duces probability for tolerogenic stimulation, which is typically mediated by excessive IL-10 
secretion. 
Inhibition of the PI3K pathway with LY294002 showed similar characteristics as in untreated 
DCs: very low IL-10 and IL-12 secretion. This result points to the assumption that the PI3K 
pathway does not influence the secretion of these interleukins if added from the start of cul-
ture, at least relative to the immature DCs. 
Also Wortmannin, the second PI3K inhibitor, provided the same results as obtained before. 
IL-10 was only slightly expressed by one healthy control and no IL-12 was secreted by any 
iDC inhibited from the start of culture. This indicates, accompanied by the results provided by 
inhibition with LY, that PI3K is not involved in the molecular events leading to the secretion 
of IL-10 and IL-12 in iDCs. 
The most significant results were obtained from DCs inhibited by Y27632 where the secretion 
of IL-10 was elevated to low-medium levels in a patient and a healthy control but as in the 
former cases, IL-10 was not measurable in the other samples and there was no IL-12 at all. 
Anyway, this result is not as significant as to suggest that ROCK pathway is involved in the 
secretion of these cytokines. The investigation of later time points will perhaps shed light on 
this possibility. 
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Mature DCs 
Also untreated DCs in their matured status reflected the expected findings: IL-10 is not pro-
duced by any cell regardless of its source and IL-12 is secreted at a high level in all DCs. This 
shows that dendritic cells, even obtained from cancer patients, secrete IL-12 in large quanti-
ties and can subsequently promote the desired TH1-type immune response. The impaired 
IL-10 secretion further excludes tolerogenic stimulation. 
The inhibition with LY mimicked the effects in untreated cells: IL-12 secretion is comparably 
high as in untreated cells and no IL-10 could be detected, strengthening the suggestion that 
PI3K is not involved in the secretion of these interleukins. This result is somewhat puzzling 
regarding the findings provided by literature, which point to the involvement of this PI3K in-
hibitor in the up regulation of IL-12 in mature dendritic cells52 and the down regulation of 
IL-1090. 
The secretion of IL-10 was impaired after Wortmannin inhibition as in untreated cells. Inter-
estingly, interleukin-12 secretion was slightly to medium diminished in four of the six DC 
samples. This observation is contradictory to that seen after LY treatment, is stochastic re-
garding the different sources and maybe due to individual characteristics or to the known dif-
fering effector functions of Wortmannin compared to LY294002. Further, the concentration 
of used PI3K inhibitors possibly needs to be adjusted to access full effects on interleukin pro-
duction. Also here, the up regulation of IL-12 after PI3K treatment, as presented in the litera-
ture, cannot be reproduced. On the other side, it was shown that a high concentration of 
Wortmannin (50mM) reduces IL-12 levels in the murine model91. 
The most interesting results could be observed from inhibition of the Rho-associated kinase, 
ROCK, which resulted in a high secretion of IL-10 in every sample, regardless of the source. 
Surprisingly, IL-12 could only be detected at a basal level and not at all in one of the patients. 
This observation clearly indicates a pivotal role of ROCK in the regulation of both IL-10 and 
IL-12 due to its strong effect upon differential interleukin secretion. The high level of IL-10 
typically induces a TH2-type of immune reaction, which is not desirable due to the promotion 
of tolerance. 
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Fig. 13: Secretion of IL-10 and IL-12 upon inhibition from start. 
 
6.3.2 Addition of PI3K and ROCK inhibitors from loading 
Untreated mDCs mimicked in principle the results obtained above: the secretion of IL-10 was 
impaired and IL-12 was produced in high amounts although, beside by one patient, not at the 
same extent. This seems to be independent from the source of DCs. It can be assumed that, 
somehow, the culture conditions were not optimal, which led to a reduced IL-12 secretion. 
Cells treated with LY294002 also had an impaired IL-10 and a pronounced IL-12 secretion, 
whose level was, with one exception, slightly lower than in untreated cells, regardless of its 
source. This finding strengthens the assumption that culture conditions reduced the IL-12 
production and further that the influence of LY294002 upon interleukin secretion is negligibly 
small although this finding is not according to other study reports. 
Also Wortmannin had no effect upon IL-10 and only a minor effect on IL-12 secretion, 
slightly increasing IL-12 production in four samples and decreasing it in one. Interestingly, a 
source-dependent effect could be seen, since the IL-12 level of all healthy controls was up 
regulated. Furthermore, this result is contradictory to the addition of the inhibitor from the 
very start of the culture, where the secretion of IL-12 was reduced or stable in each sample. 
Investigating the reasons for the different secretion patterns, leads to the conclusion that either 
the time point of Wortmannin addition or its effector function is causal for these observations. 
Finally the up regulation of IL-12 is consistent with findings presented in literature. 
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Once again, ROCK inhibition offered completely altered secretion of IL-10 and IL-12, with a 
medium-high to high production of the first and almost completely impaired secretion of the 
latter. This is in accordance to the secretion levels present after inhibition from the start and is 
not source-dependent. On the other side, the assumption that ROCK is important in mediating 
signals for the regulation of interleukin 10 and 12 is further strengthened and that impaired 
ROCK signaling promotes the activation of a tolerogenic immune response in both, healthy 
controls and cancer patients. 
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Fig. 14: Secretion of IL-10 and IL-12 upon inhibition from loading. 
 
6.3.3 Addition of PI3K and ROCK inhibitors from maturation 
The investigation of untreated DCs showed that IL-10 was almost absent in all samples and, 
curiously, IL-12 secreted at low to medium levels beside one healthy control and one patient, 
where it was highly expressed. In comparison to earlier time points, the IL-12 secretion mark-
edly diminished and so strengthens the assumptions of problems in culture conditions. 
Cells treated with LY294002 also had an impaired IL-10 and a pronounced IL-12 secretion, 
whose level was slightly lower than in untreated cells, regardless of its source. One healthy 
control’s derived DCs showed a more profound reduction in IL-12 secretion but considering 
that in untreated cells the IL-12 level of this control was far higher than in the other samples 
some caution is advised. In conclusion, the results are according to former findings, which 
indicate that PI3K inhibition with LY294002 does only minor, if any, affect the secretion of 
these cytokines; also not if applied at different time points. 
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mDCs treated with Wortmannin from the maturation step on, did not secret any IL-10 and low 
to medium amounts of IL-12 comparable to untreated cells. The effect of enhanced IL-12 
production, as in DCs inhibited from the loading on and as in literature mentioned, could not 
be reproduced. A time dependence of Wortmannin addition can be argued to be the cause for 
this discrepancy but also the effect of enhanced IL-12 secretion, as seen before, is only slight 
and can be due to culture conditions, too. 
ROCK inhibition had the highest impact on IL secretion with almost total absence of IL-12 
but a high production of IL-10. Mentionable, the Interleukin 10 level was slightly diminished 
in one patient and one healthy control, presumably due to individual characteristics. Also the 
inhibition from loading on elicits a pivotal role of ROCK in cytokine secretion, as seen be-
fore, and justifies further investigation of ROCK in the maturation of dendritic cells.  
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Fig. 15: Secretion of IL-10 and IL-12 upon inhibition from maturation. 
 
6.4 Proliferation assay (mixed-leukocyte-reaction) 
Since we showed that human DCs maturation, studied according to morphology, phenotype 
and IL production, was strongly affected by chemical inhibition of PI3K and ROCK, we fur-
ther investigated whether such effects correlated with impaired capability to stimulate lym-
phocyte proliferation, a hallmark of mature and fully active DCs, measured by means of a 
mixed lymphocyte reaction (MLR). The proliferation rate is normalized to the proliferative 
potential of immature cells, which is set to the value of 1. The proliferation rate of the lym-
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phocytes induced by mature DCs is given as a relative proliferation rate compared to that 
shown by immature cells. 
6.4.1 Addition of PI3K and ROCK inhibitors from start 
Untreated mDCs, both from healthy controls and patients, showed a high rate in the stimula-
tion of proliferation of lymphocytes. This is a characteristical trait of fully mature dendritic 
cells and reflects good culture conditions. 
LY-inhibited mDCs markedly reduced the potential to induce T cell proliferation, which is 
neither source-dependent nor individual-specific. 
The effect of Wortmannin was stronger than that of LY and led to a reduction in T cell prolif-
eration to the level of iDCs or slightly above. Both, LY and Wortmannin inhibition indicate 
an important function of PI3K in the induction of a proper T cell activation, corresponding to 
phenotypical analysis where the expression of relevant surface markers was reduced. 
Y27632 inhibition from the start of culture significantly increased the potential to induce 
T cell proliferation in four samples. In the remaining two samples, one patient and one 
healthy control, the rate was equal or slightly lower than in the untreated cells. Interestingly, 
this is contradictory to the absence of IL-12 which usually promotes T cell activation and 
points toward an IL-12 independent mechanism. 
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Fig. 16: relative proliferation rate of lymphocytes upon DC inhibition from start. 
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6.4.2 Addition of PI3K and ROCK inhibitors from loading 
The addition of selective inhibitors from the loading on almost totally mimicked the results 
obtained from longer exposure, leading to the conclusion that the capability to induce T cell 
proliferation is not depending on prolonged exposure to the inhibitors.  
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Fig. 17: relative proliferation rate of lymphocytes upon DC inhibition from loading. 
 
6.4.3 Addition of PI3K and ROCK inhibitors from maturation 
If the inhibitors were added on from the maturation of DCs, LY, Wortmannin and Y27632 
mimicked the former results. So, the time-window of inhibitor addition does not influence the 
strength of T cell activation and administration from maturation on is sufficient to provoke 
these effects. 
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Fig. 18: relative proliferation rate of lymphocytes upon DC inhibition from maturation. 
 
6.5 Phagocytosis assay (FITC-dextran uptake) 
In order to be able to induce proliferation of lymphocytes, DCs need to phagocyte exogenous 
antigens. Therefore, such characteristic is a typical feature of iDCs, while once they are 
loaded with an antigen, mDCs loose the capability to endocyte further. Since we observed that 
the inhibition of PI3K and ROCK pathways impaired human DCs in vitro maturation, we in-
vestigated whether such morphological, phenotypical and functional characteristic correlated 
with the increased amount of activities, typical for iDCs. The phagocytosis property of DCs is 
determined through the rate of FITC-dextran uptake, which is given in percentage of cells, 
which take up the labelled dextran. In order to determine the effects of maturation on the 
phagocytotic capability, the cells were induced by addition of CCL19, the ligand of CCR7, a 
surface marker expressed exclusively by mDCs. 
6.5.1 Addition of PI3K and ROCK inhibitors from start 
Immature DCs 
Immature dendritic cells, regardless of untreated or supplemented with selective inhibitors, 
showed a very high potential to phagocyte spontaneously and were unable to respond to 
CCL19 activation, according to results from literature. This suggests that neither PI3K nor 
ROCK is crucial for phagocytosis relative to the immature stage of human DCs. 
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Mature DCs 
Typically, untreated and matured DCs were unable or only slightly able to perform spontane-
ous phagocytosis. Also upon CCL19 induction, hardly any improvement could be observed, 
which corresponds to the results reported in literature. 
Inhibition by LY294002 from the start on showed an improved phagocytic capability of 
mDCs in spontaneous phagocytosis to a medium-high level and a somewhat higher capacity 
of patents’ derived DCs than of their healthy counterparts. Upon induction with CCL19 the 
phagocytosis was further enhanced. 
Upon Wortmannin treatment, spontaneous phagocytosis was comparably high like after 
LY294002 inhibition, with one minor individual–specific exception where it was slightly in-
creased. Induced phagocytosis improved the capacity to phagocyte, regardless of its source. 
PI3K inhibition from the start on, leads to an improved phagocytosis in mDCs, which points 
to an important function of PI3K in this property of dendritic cells, by mediating maturation at 
all or, possibly, by directly influencing phagocytosis-related pathways. 
ROCK inhibition elicited the highest impact on phagocytosis capacity increasing it to the rate 
of immature DCs, independent of CCL19 induction. This could be observed in both, the 
healthy controls and the patients. Interestingly, the high rate of phagocytosis is a typical hall-
mark of iDCs. Therefore, ROCK signalling appears to be important in functional maturation 
of DCs, possibly by impairing phagocytosis which is not surprising, as ROCK is known to be 
involved in the regulation of the cytoskeleton. 
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Fig. 19: relative FITC-dextran uptake upon inhibition from start. 
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6.5.2 Addition of PI3K and ROCK inhibitors from loading 
Typically, untreated and matured DCs were unable or only slightly able to perform spontane-
ous phagocytosis. Also upon CCL19 induction, hardly any improvement could be observed 
which corresponds to the results shown in literature. 
The inhibition of PI3K with LY294002 from the loading on had similar effects as the inhibi-
tion from start: improved spontaneous phagocytic capability, which was even more pro-
nounced upon addition of CCL19. The only difference was that the phagocytosis was slightly 
lower compared to the earlier time point. This effect seems to be due to the shorter time of 
incubation with LY294002. 
The effects caused by Wortmannin mimicked in general those of LY294002 although sponta-
neous phagocytosis was higher in cancer patients’ derived DCs compared to LY294002 and 
also to the healthy controls. CCL19 enhanced the phagocytic potential further, apart from one 
healthy control in which induced phagocytosis led to a reduced potential. The assumptions 
made upon PI3K function from the start of culture were confirmed and time-dependence was 
additionally noticed. 
Y27632 increased the phagocytic capacity almost to the rate of immature dendritic cells. This 
could be strengthened by the addition of CCL19, which was different from the former series 
of experiments, where also the spontaneous phagocytosis had equal rates compared to imma-
ture cells. It seems that the time point at which ROCK inhibitor is administered is crucial for a 
total induction of phagocytosis. Anyway, the assumption that ROCK is an important mediator 
in phagocytosis is confirmed. 
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Fig. 20: relative FITC-dextran uptake upon inhibition from loading. 
 
6.5.3 Addition of PI3K and ROCK inhibitors from maturation 
Characteristically, untreated and matured DCs were unable or only slightly able to perform 
spontaneous phagocytosis. Also upon CCL19 induction, hardly any improvement could be 
observed which corresponds to findings presented in literature. 
PI3K inhibition with LY correlated with increased spontaneous phagocytosis to a medium 
level, which is similar to the inhibition from loading and therefore also lower than after pro-
longed exposure. CCL19 addition caused a higher phagocytotic potential. 
Exposure to Wortmannin from maturation on improved the potential to phagocyte to the level 
of inhibitor addition from loading on, spontaneously and induced. Again, this effect seems to 
be source-dependent as the phagocytic capability is slightly but significantly higher in DCs 
derived from cancer patients. Taken together, former findings are approved and an admini-
stration of LY and Wortmannin from the start of culture on brings about the highest impact on 
phagocytosis 
In contrast, ROCK inhibition increased the level of spontaneous phagocytosis in nearly all 
samples to that of iDCs. CCL19 induced phagocytosis further enhanced the capability of the 
cells. This affirms the crucial role of ROCK in phagocytosis and shows that Y27632 addition 
is not time-dependent. 
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Fig. 21: relative FITC-dextran uptake upon inhibition from maturation. 
 
6.6 Migration assay (Transwell assay) 
Finally, we investigated the effects of PI3K and ROCK inhibition on the migratory potential, 
which as well as the phagocytosis is a hallmark of immature DCs. 
The migration assay is carried out as a transwell assay. The results are given in percentage of 
migrated cells (spontaneous or induced) relative to the total cell number.  
6.6.1 Addition of PI3K and ROCK inhibitors from start 
Immature DCs 
iDCs, regardless of their source and of the used inhibitors, possessed a very high potential in 
spontaneous and induced migration, which is in accordance to findings from literature. 
 
Mature DCs 
According to literature, the potential of untreated DCs to spontaneously migrate was down 
regulated to a basal level upon maturation and the addition of CCL19 reduced the capability 
further in two patients and two healthy controls. 
Under the influence of LY294002 spontaneous migration was enhanced in five samples but 
only to a minor extend. Interestingly, this effect was completely different if the cells were 
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supplied with CCL19 because in this case the rate of migrating cells increased to a very high 
level, comparable to that of immature DCs. 
Wortmannin administration mimicked upon CCL19-induced migration the effects of LY. The 
capability to migrate spontaneously in cancer patients’ derived DCs was at the level of un-
treated cells or underneath. In the healthy control this was somewhat higher. Overall, LY 
stronger induced the potential to migrate spontaneously, especially in patients’ cells. 
LY294002 and Wortmannin treatment influences spontaneous migration only minor but sup-
plementation with CCL19 significantly increases the ability to migrate, which indicates a 
function of PI3K in CCL19-CCR7 mediated migration. 
In contrast, inhibition with Y27632 increased the spontaneous migratory potential of DCs to a 
high level independent of its source. CCL19 further enhanced migration to a comparable level 
like in immature DCs in two patients and two controls. In the remaining samples CCL19 led 
to a slight decrease in parallel to spontaneous migration. In contrast to inhibition of PI3K, also 
the ability to spontaneously migrate is significantly enhanced upon depletion of ROCK, 
which entitles ROCK to be a negative regulator of migration. This is not surprising, as ROCK 
is known to be a pivotal player in the regulation of the cytoskeleton. 
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Fig. 22: migratory rate of DCs upon inhibition from start. 
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6.6.2 Addition of PI3K and ROCK inhibitors from loading 
Untreated cells mimicked the effect seen before with the minor exception that in every case 
CCL19 further enhanced migration. 
Upon treatment with LY former results can be affirmed as well except that the induction with 
CCL19 did not raise the migratory potential at the same extend any more, indicating a de-
pendence on the time of LY administration. 
Wortmannin treatment mimicked the results from prolonged exposure as seen before although 
the effect of CCL19 induction was not as pronounced, delivering evidence for time dependent 
effects of Wortmannin. Further, a source-dependence was no longer evident. 
The later addition of the ROCK inhibitor even exceeded the capability to migrate seen after 
prolonged exposure but was less dependent upon CCL19 supplementation. This result is in 
accordance with former findings and indicates that the time point of inhibitor administration 
is crucial for optimal modulation of migration. 
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Fig. 23: migratory rate of DCs upon inhibition from loading. 
 
6.6.3 Addition of PI3K and ROCK inhibitors from maturation 
As expected, untreated cells mimicked the effects seen after inhibition from loading with one 
minor exception: DCs derived from one patient had a slightly reduced potential to migrate 
upon CCL19 induction.  
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Also, LY treatment revealed similar results like with earlier time points of inhibitor admini-
stration. Interestingly, the later addition of the PI3K inhibitor decreased the induced migratory 
potential further and leveled at a medium rate strengthening the importance of PI3K in in-
duced migration. 
Time-dependence could also be detected in Wortmannin treated cells, where the level of 
spontaneous migration was lower or equal to the rate of untreated cells. The potential of in-
duced migration further decreased in comparison to longer exposure times, although to a 
lower extend in the healthy controls. Also Wortmannin inhibition showed the importance of 
PI3K in induced migration. 
In the case of Y27632 treatment previous findings were strengthened, revealing a very high 
capability to migrate spontaneously and induced by CCL19. The effect upon migration was 
especially high if the inhibitor was added from loading or maturation on, leading to the con-
clusion that a short incubation with Y27632 is sufficient to optimally enhance migration in 
DCs. 
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Fig. 24: migratory rate of DCs upon inhibition from maturation. 
 
6.7 Viability assay 
In order to finally investigate the role of PI3K and ROCK during DC maturation, we investi-
gated their effects on cell viability as well, using a viability assay based on Annexin-V-FITC 
detection. The viability of mDCs was decreased to a rate of about one quarter of the total cell 
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number independent of their source. Cells were cultured in presence of the relative inhibitors 
from the start of the culture. 
6.7.1 Addition of PI3K and ROCK inhibitors from start 
The viability of untreated mDCs levelled between approximately 70% and 81% and was 
markedly reduced if the PI3K inhibitors LY or Wortmannin were added from the very start of 
the culture. LY-treated mDCs showed a decrease of viability to 50%-60%, Wortmannin 
treated cells to 42%-55% with one exception where viability was at 60% and even higher than 
upon LY treatment. Interestingly, ROCK inhibition with Y27632 only marginally reduced the 
viability of mDCs to 65%-80%, in spite of its high impact on functional and phenotypical 
properties, especially of mature dendritic cells and the administration of a relatively high dose 
(40mM), regarding literature. These observations were independent from the source of DCs 
but showed individual variations. 
In conclusion, it has been shown that the inhibition of PI3K reduced the viability of mDCs 
with both inhibitors although stronger upon Wortmannin, which strengthens the assumption 
of PI3K as a pivotal player in the survival of mDCs. Y27632 does not alter the viability as 
much as with PI3K inhibitors and therefore ROCK does not seem to be a key component for 
DC survival. On the other side, the high level of the apoptosis-related surface marker CD95L 
in Y27632-treated cells could be important in mediating cell survival, as CD95L is strongly 
down regulated upon PI3K inhibition, accompanied by increased phagocytosis (Fig. 25). 
 
Fig. 25: percentage of viable DCs upon inhibition from start. 
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6.8 Western blot 
Due to the fact that an indirect analysis of the PI3K and ROCK pathways through cell mor-
phology, phenotype and different functionalities showed that they play a crucial role for the 
final maturation of human DCs and that they may be dependent to different extends on indi-
vidual characteristics as well as from their source, i.e. healthy people or cancer patients, we 
investigated the expression of such kinases in untreated as well as inhibited cell cultures of 
human DCs by WB analysis. The cytoplasmatic fractions of the protein lysates were obtained 
by Frackelton lysis from mDCs derived from patient A, suffering from colon cancer. These 
cells were incubated without or with inhibitors from the start of the culture. 
6.8.1 Ezrin/Moesin/Radixin 
Ezrin and Moesin, members of the ERM protein family, are crucial for linking cell surface 
and cytosolic proteins to the actin skeleton. One of the most prominent activators of Ezrin is 
ROCK, whose inhibition is expected to alter expression levels of Ezrin. 
 
Ezrin/Moesin/Radixin 
The polyconal rabbit antibody against Ezrin/Moesin/Radixin detects endogenous levels of the 
ERM proteins Ezrin, Radixin (80kDa) and Moesin (80kDa) and binds to residues surrounding 
Thr567. 
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Fig. 26: Western blot of ERM proteins and actin. 
 
Analysis of ERM protein expression levels showed no influence of Wortmannin and only a 
minor of LY. On the contrary, Y27632 totally impaired the expression of ERM proteins in the 
cytoplasm, indicating either no expression at all or an altered localization (Fig. 26). This is not 
surprising as, at least Ezrin, a crucial downstream target of ROCK is. 
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pEzrin/pMoesin/pRadixin 
The presence of phosphorylated ERM proteins is detected with a polyclonal Ab raised against 
phosphorylation at Thr567 (Ezrin), Thr564 (Radixin) and Thr558 (Moesin) only, which dis-
rupts the amino- and carboxy-terminal association and may alter conformation and function of 
ERM proteins. 
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Fig. 27: Western blot of ERM protein phosphorylation and actin. 
 
The phosphorylation of ERM proteins at specific residues significantly decreased upon LY 
and Y27632 treatment. The effect of Y27632 is not surprising, as total ERM proteins could 
not be detected (Fig. 27). The contradictory results showed upon PI3K inhibition either with 
LY or Wortmannin, may reside either in the different effects driven by the 2 inhibitors or in 
the differences observed in the loading. Further experiments in this direction are required in 
order to find out the real effects of PI3K upon ERM phosphorylation pathway in human DCs.  
6.8.2 p38, MEK and JNK 
To assess the impact upon MAPK pathways, which are known to diversely affect cellular 
processes like proliferation and differentiation, the expression levels of total and phosphory-
lated p38, MEK and JNK were measured. Further, MEK and JNK pathways have been shown 
to be modified by PI3K signalling. 
 
p38 
The p38 antibody binds to amino acids 213-360 at the C-terminus of p38. It is a polyclonal 
rabbit antibody. 
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Fig. 28: Western blot of p38 and actin. 
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The expression of p38 did not seem to be affected by addition of PI3K or ROCK inhibitors 
(Fig 28). 
MEK1/2 
Polyclonal MEK1/2 antibody detects endogenous levels of total MEK1/2 protein with a size 
of 45kDa and was produced in rabbit. 
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Fig. 29: Western blot of MEK1/2 and actin. 
 
The expression of MEK 1/2 did not seem to be affected by addition of Wortmannin or ROCK 
inhibitors while upon inhibition with LY, the expression of MEK was abrogated (Fig. 29). 
 
pMEK 
The presence of phospho-MEK1/2 (45kDa) was investigated using a polyclonal rabbit anti-
body raised against the phosphorylation sites at Ser217/221. 
45kDa
C LY YW
Actin
 
Fig. 30: Western blot of MEK phosphorylation and actin. 
 
The phosphorylation pattern of MEK1/2 did mirror that observed for MEK1/2 expression, 
suggesting that the only effect observed upon LY addition (Fig. 30), drive the expression pat-
tern of MEK1/2 and not its phosphorylation, suggesting a mechanism involved in long-term 
expression control, possibly a transcriptional one. Further experiments in this direction are 
required to determine the real significance of such hypothesis. 
 
JNK 
Endogenous level of total JNK was assessed with a polyclonal rabbit antibody detecting iso-
forms of JNK at the size of 46kDa (JNK1) and 54kDa (JNK2/3). 
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Fig. 31: Western blot of JNK and actin. 
 
Both, LY294002 and Y27632 abrogated the expression of JNK1 in the cytoplasm. JNK 2/3 
expression seemed unaffected by any inhibition (Fig. 31). Further experiments are required in 
order to determine the significance of such findings. 
6.8.3 B-Raf and C-Raf 
B-Raf and C-Raf are known to be closely linked to the MAPK pathway, of which the MEK 
and JNK pathway can be modulated by PI3K signalling, and were investigated to assess the 
effects of selective PI3K and ROCK inhibitors. 
 
B-Raf (C19) 
The polyclonal rabbit antibody, binding the C-terminal region, detects endogenous levels of 
B-Raf at the size of 62kDa and 95kDa. 
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Fig. 32: Western blot of B-Raf (C-19) and actin. 
 
Apparently both LY and ROCK inhibitions abrogated the expression of B-RAF (C-19), while 
Wortmannin has no effects on the 62kDa form and abrogated the expression of the 95kDa one 
(Fig. 32). Further experiments are required in order to determine the significance of such find-
ings. 
 
B-Raf (H145) 
The B-Raf (H-145) polyclonal rabbit antibody binds to amino acids 12-156 of human B-Raf 
at the size of 62kDa and 95kDa. 
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Fig. 33: Western blot of B-Raf (H145) and actin. 
 
Interestingly, only ROCK inhibition impaired B-Raf expression in mature DCs at a size of 
62kDa and 95kDa. LY294002 and Wortmannin only reduced the level at 62kDa (Fig. 33), 
which is contradictory to the results presented by detection with the C-terminal binding anti-
body and has to be investigated further. 
 
C-Raf 
Monoclonal mouse C-Raf antibody detects total C-Raf levels at 74kDa. 
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Fig. 34: Western blot of C-Raf and actin. 
 
LY294002 had a high impact upon C-Raf, impairing its expression completely. The same in-
fluence could not be detected for Wortmannin or Y27632, although the high background pos-
sibly disguised the expression after treatment with the ROCK inhibitor (Fig. 34). Further ex-
periments are required in order to determine the significance of such findings. 
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7 DISCUSSION 
The main goal of this diploma thesis was to investigate the involvement of PI3K and ROCKII 
pathways in the in vitro maturation of dendritic cells, cultured from peripheral-blood mono-
cytes. Additionally, this thesis aimed to show the potential effects of tumor establishment 
upon DC maturation according to PI3K and ROCKII. For these reasons all experiments were 
performed on DCs derived from healthy volunteers and from patients suffering from different 
types of cancer. The preliminary results showed that both PI3K and ROCKII clearly affected 
different aspects of DC maturation. In the experiments described in this thesis, PI3K kinase 
activity was inhibited by the use of two distinct and specific chemical compounds: LY294002 
and Wortmannin, which affected the PI3K pathway mainly in different ways.  
Both the PI3K inhibitors showed similar effects on DC morphology: the addition of either 
LY294002 or Wortmannin impaired the establishment of the typical mature morphology, 
since the treated cells remained round and free in the supernatant, unable to develop the typi-
cal dendrites and adherence showed by normal, mature DCs. These changes in DC morphol-
ogy were accompanied by an impaired expression of mature markers on DC surface. The ef-
fect on the surface markers expression was different according to the type of inhibitor used, 
suggesting that the two chemical substances specifically affect different arms of the PI3K pat-
tern. Further statistical significant studies in this direction are required. From the functional 
point of view, the cells treated with both PI3K inhibitors showed impaired ability to trigger 
T cell proliferation, suggesting that both PI3K pathways, alternatively impaired by the two 
inhibitors, are required for an efficient T cell activation. 
Nevertheless, surprisingly, secretion of interleukin 10 and 12 appeared to be only slightly in-
fluenced by LY and Wortmannin, indicating that PI3K has minor if any effects on this proc-
ess, although other groups showed that PI3K may affect the regulation of IL-1252. These dif-
ferences might be explained with different ways of culturing the cells and/or cell source. 
From our results, it appears that an active PI3K is required by human DCs during the matura-
tion, upstream of the loss of phagocytosis upon loading and maturation. Indeed, cells treated 
with PI3K inhibitors maintain the capability to phagocyte even after being loaded and ma-
tured. On the contrary, induction by CCL19 increased this process. Interestingly, it appears 
that exposure to the inhibitor from the start of the culture increased the effects. This may indi-
cate that a prolonged exposure is required or that the exposure effects are stronger when ap-
plied to immature cells. Further studies are required to answer this question. The same effects 
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although even stronger were observed regarding migration potentialities, pointing out that 
PI3K seems to be required by human DCs to acquire the mature, functional characteristics. 
PI3K inhibition was always accompanied by a decrease in cell viability. Although further 
studies regarding a defined titration of the inhibitors may be advisable, it appears that PI3K 
strongly affects DC viability, in accordance with its strong effects on cell metabolism. West-
ern blot analyses indicates that PI3K inhibition through addition of LY294002 but not of 
Wortmannin affects the protein levels of C-Raf, B-Raf, JNK1, MEK and the ERM proteins, as 
well as their phosphorylation. These findings require more investigation in this direction to 
determine the real significance of PI3K inhibition on MAPK and ERM signalling pathways. 
Although new experiments are required, the preliminary results showed that PI3K is required 
to trigger the maturation of human DCs and that it acts differently according to morphologi-
cal, phenotypical and functional processes. PI3K appears to be involved in at least two differ-
ent pathways, which respond alternatively to PI3K inhibition through LY294002 or Wort-
mannin. 
Only the combination of the two pathways triggers the proper maturation of human DCs, at 
least in in vitro culture conditions.  
During this thesis, the role of ROCKII upstream of DC maturation was observed as well by 
analysing the effects of a selective, chemical inhibition of this pathway through the addition 
of Y27632 to the cell culture. 
Morphological analysis revealed an important function of ROCKII in the regulation of the 
formation of dendrites as well as of the development of the adherent phenotype, a typical fea-
ture of mature DCs. 
Although the effect of ROCKII inhibition on phenotype of DCs was not as pronounced as that 
of PI3K, this feature appears to be as well affected by tumor establishment, since ROCKII 
inhibition exerted different effects according to the source of the DCs (healthy controls or pa-
tients), regarding the expression of mature, surface markers. 
Interestingly, ROCKII inhibition very strongly impaired the secretion of IL-12, while power-
fully up regulating that of IL-10. This fact points out that ROCKII seems to act principally on 
cytokine secretion. The analysis of T cell proliferation capability showed that although IL-12 
secretion is depleted, mDCs possess a high potential to induce T cells. This is somewhat sur-
prising, as it points to an interleukin 10/12 totally independent mechanism in T cell activation. 
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ROCKII is also necessary in the regulation of phagocytosis as its depletion leads to a high 
phagocytosis rate, comparable to immature DCs. This feature may be explained by the known 
role as regulator of the cytoskeleton, played by ROCKII. 
Also an enhanced migratory potential could be observed if ROCKII was inhibited, strengthen-
ing its important function in the regulation of the cytoskeleton. Further a short incubation with 
Y27632 is sufficient to strongly promote migration. 
Interestingly, ROCKII inhibition had the lowest impact upon cell death. This is accompanied 
by a high expression rate of the apoptosis-related surface marker CD95L, possibly mediating 
cell survival. 
Western blotting showed that ROCKII appears to have a positive effect on the levels of ERM 
proteins, which is not surprising as at least Ezrin is a known downstream target of ROCKII 
signalling. Interestingly, also JNK1 and B-Raf appear to be influenced by the activity of 
ROCKII. 
In conclusion, these results show an important function of ROCKII in the phenotypical and 
functional maturation of DCs. Specific characteristics associated with the cytoskeleton are 
affected by ROCKII signalling. One interesting finding is that Y27632-treated cells produce 
high amounts of IL-10 and low levels of IL-12 but can still effectively stimulate T cell prolif-
eration and it can be assumed that this fact is due to an interleukin 10/12 independent mecha-
nism. Further, it appears that ROCKII activity is differently modulated in DCs derived from 
healthy controls in comparison to those derived from patients suffering from different types of 
cancer. This suggests that the establishment of the tumor may affect specific cell pathways of 
the APC, possibly in order to diminish their ability to induce the immune response against 
cancer-specific antigens. 
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